DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
|You are receiving this because you have an account on www.oneGRAVESvoice.com|
|To unsubscribe from these emails, click here|
Trusted Resources: News & Meetings
Latest announcements and gatherings
The U.S. Food and Drug Administration (FDA) approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease, a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to be pushed forward and bulge outwards (proptosis). This approval represents the first drug approved for the treatment of thyroid eye disease.
The approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non-surgical treatment option,” said Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research.
Tepezza was approved based on the results of two studies (Study 1 and 2) consisting of a total of 170 patients with active thyroid eye disease who were randomized to either receive Tepezza or a placebo.
More from Teprotumumab News:
More from Teprotumumab Research:
(Author: Raymond S. Douglas)
Evidence & EducationPreoperative Clinical Features of Reactivated of Graves’ Orbitopathy After Orbital DecompressionPurpose: To investigate the incidence a...
Videos & VisualsWhat is Strabismus? – Interview With Dr. Gappyhttps://www.youtube.com/watch?v=InfpXPMR...
News & MeetingsNew Data from Phase 3 Teprotumumab Trial Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Mo...Horizon Pharma plc today announced that ...
Evidence & EducationSurgical Treatment of Diplopia in Graves’ Orbitopathy PatientsPurpose: To review the authors' current...
People & PlacesCasey Eye Institute – Thyroid Eye Disease CenterAs part of Oregon Health & Science U...
News & MeetingsGraves’ and Thyroid Eye Disease Support Group MeetingThis event is hosted by Graves' Dise...
Evidence & EducationRelated Quality of Life Questionnaire Specific to Dysthyroid Ophthalmopathy Evaluated in a Population of Patients Wi...Objective: The aim of this study was to...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.